{"id":578785,"date":"2021-12-13T08:44:01","date_gmt":"2021-12-13T08:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=578785"},"modified":"2021-12-13T08:44:01","modified_gmt":"2021-12-13T08:44:01","slug":"the-novel-ocular-drug-delivery-devices-market-is-projected-to-grow-at-a-cagr-of-15-till-2030-claims-roots-analysis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-novel-ocular-drug-delivery-devices-market-is-projected-to-grow-at-a-cagr-of-15-till-2030-claims-roots-analysis_578785.html","title":{"rendered":"The novel ocular drug delivery devices market is projected to grow at a CAGR of 15%, till 2030, claims Roots Analysis"},"content":{"rendered":"
\n
\"The<\/a><\/div>\n
\n
Roots Analysis Logo<\/div>\n<\/div>\n<\/div>\n
Roots Analysis has announced the addition of the \u201cNovel Ocular Drug Delivery Devices Market, 2021 \u2013 2030\u201d report to its list of offerings.<\/div>\n

The delivery of drugs in ocular regions is known to be considerably more challenging; several pharmaceutical companies are actively undertaking initiatives to identify novel approaches for safe and efficient administration of therapies to eyes<\/em><\/strong><\/p>\n

 <\/p>\n

Roots Analysis<\/strong><\/a> has announced the addition of the “Novel Ocular Drug Delivery Devices<\/strong><\/a> Market, 2021 – 2030<\/strong>” report to its list of offerings.<\/p>\n

 <\/p>\n

Over the years, a number of companies have developed several novel and advanced drug delivery devices, which are reported to be capable of addressing the known challenges in this domain. The anticipated growth in the patient population for such disorders is likely to increase demand for effective and patient centric ocular drug delivery devices.<\/p>\n

 <\/em><\/strong><\/p>\n

To order this 200+ page report, which features 90+ figures and 115+ tables, please visit this- <\/em><\/strong>https:\/\/www.rootsanalysis.com\/reports\/novel-ocular-drug-delivery-devices-market.html<\/a><\/p>\n

 <\/p>\n

Key Market Insights <\/strong><\/p>\n

Over 45 novel ocular drug delivery devices have either been approved or are being developed <\/strong><\/p>\n

Currently, 13% of such drug delivery devices are marketed, while majority (44%) of the systems are being evaluated in preclinical and discovery stages. Further, most (88%) of these devices are intended for the delivery of small molecule-based therapies.<\/p>\n

 <\/p>\n

Close to 80% of the novel ocular drug delivery devices in the pipeline are implants<\/strong><\/p>\n

Inserts and punctal plugs represent 10% of the development pipeline, each. Further, majority (60%) of such drug delivery devices are biodegradable. It is also worth mentioning that most (75%) of the ocular drug delivery device developers are based in North America, primarily in the US.<\/p>\n

 <\/p>\n

Clinical trials registered in this domain have increased at a CAGR of 29%, during 2018-2021<\/strong><\/p>\n

A number of clinical studies focused on the evaluation of novel drug delivery devices are currently ongoing worldwide. Of the total, close to 55% of the studies have already been completed, followed by 33% trials which are currently active and recruiting patients.<\/p>\n

 <\/p>\n

Over 1,145 patents related to novel ocular drug delivery devices have been granted \/ filed <\/strong><\/p>\n

There was significant increase in the number of patent applications filed over the last few years. Interestingly, more than 100 patents were filed \/ granted in 2020. Further, around 45% of the patents were filed in North America. It is worth highlighting that most of the patents were granted \/ filed for ocular implants.<\/p>\n

 <\/p>\n

Partnership activity within this domain has increased at a CAGR of 18%, between 2017 and 2021<\/strong><\/p>\n

Research and development agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product commercialization agreements (12%), product commercialization and development agreements (12%), and product distribution agreements (8%).<\/p>\n

 <\/p>\n

More than USD 3.5 billion has been invested by both private and public investors in this domain <\/strong><\/p>\n

It is important to mention that, between pre-2011 and 2021, majority of the funding amount was raised through secondary offerings (68%) and debt financing (20%). Further, most (93%) of the funding rounds were reported in the US.<\/p>\n

 <\/strong><\/p>\n

North America and Europe are anticipated to capture over 88% of the market share, by 2030<\/strong><\/p>\n

The current market is driven by sales of novel ocular drug delivery devices designed to treat non-infectious uveitis (over 32%), followed by those targeting diabetic macular edema (22%) and glaucoma (13%). Further, ocular drug delivery inserts currently capture the dominant share (90%) of the market (in terms of sales-based revenues<\/em>); this trend is unlikely to change in the foreseen future.<\/p>\n

 <\/p>\n

To request a sample copy \/ brochure of this report, please visit this<\/em><\/strong><\/p>\n

https:\/\/www.rootsanalysis.com\/reports\/novel-ocular-drug-delivery-devices-market\/request-sample.html<\/a><\/p>\n

 <\/strong><\/p>\n

Key Questions Answered<\/strong><\/p>\n